NASDAQ:XERS

Xeris Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy XERS

*Your capital is at risk

$5.89

-0.110 (-1.83%)

At Close: Jun 03, 2026

Xeris Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -36.34. In total, the insiders bought 4.12M and sold 1.83M XERS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-36.34
● Buy	4.12M shares
● Sell	1.83M shares
52% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Jan 30, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -36.34. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Nov 14, 2025 Buy	Common Stock M-Exempt	Shannon John Patrick Jr See Remarks	Officer	87 100 Value: $135.0K
Nov 13, 2025 Buy	Common Stock M-Exempt	Shannon John Patrick Jr See Remarks	Officer	8 970 Value: $13.9K
Nov 13, 2025 Sell	Common Stock S-Sale	Shannon John Patrick Jr See Remarks	Officer	23 242 Value: $173.4K
Nov 13, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Shannon John Patrick Jr See Remarks	Officer	8 970 Value: $13.9K
Nov 11, 2025 Sell	Common Stock S-Sale	Hecht Beth See Remarks	Officer	16 667 Value: $123.3K
Oct 02, 2025 Sell	Common Stock F-InKind	Mcculloch Kevin See Remarks	Officer	733 Value: $6K
Oct 02, 2025 Sell	Common Stock F-InKind	Mcculloch Kevin See Remarks	Officer	733 Value: $6K
Sep 11, 2025 Sell	Common Stock J-Other	Mcculloch Kevin See Remarks	Officer	2 000 Value: $0
Sep 11, 2025 Sell	Common Stock J-Other	Mcculloch Kevin See Remarks	Officer	2 000 Value: $0
Sep 11, 2025 Sell	Common Stock S-Sale	Persky Marla Director	Director	15 500 Value: $119.6K
Sep 11, 2025 Sell	Common Stock S-Sale	Persky Marla Director	Director	15 500 Value: $119.6K
Aug 28, 2025 Buy	Common Stock M-Exempt	Sherman Jeffrey W Director	Director	47 040 Value: $313.3K
Aug 28, 2025 Sell	Common Stock S-Sale	Sherman Jeffrey W Director	Director	42 232 Value: $334.5K
Aug 28, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Sherman Jeffrey W Director	Director	47 040 Value: $313.3K
Aug 28, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Sherman Jeffrey W Director	Director	47 040 Value: $313.3K
Aug 28, 2025 Sell	Common Stock S-Sale	Sherman Jeffrey W Director	Director	42 232 Value: $334.5K
Aug 28, 2025 Buy	Common Stock M-Exempt	Sherman Jeffrey W Director	Director	47 040 Value: $313.3K
Aug 13, 2025 Sell	Common Stock S-Sale	Johnson John Director	Director	107 500 Value: $786.5K
Aug 13, 2025 Sell	Common Stock S-Sale	Johnson John Director	Director	107 500 Value: $786.5K
Aug 12, 2025 Sell	Common Stock S-Sale	Halkuff Dawn Director	Director	42 500 Value: $309.2K
Aug 12, 2025 Sell	Common Stock S-Sale	Halkuff Dawn Director	Director	42 500 Value: $309.2K
Aug 01, 2025 Sell	Common Stock F-InKind	Shannon John Patrick Jr See Remarks	Officer	36 918 Value: $198.6K
Aug 01, 2025 Sell	Common Stock F-InKind	Mcculloch Kevin See Remarks	Officer	14 651 Value: $78.8K
Aug 01, 2025 Sell	Common Stock F-InKind	Mcculloch Kevin See Remarks	Officer	14 651 Value: $78.8K
Aug 01, 2025 Sell	Common Stock F-InKind	Shannon John Patrick Jr See Remarks	Officer	36 918 Value: $198.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT XERIS PHARMACEUTICALS INC

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhi...

Read Full Profile Here